Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
$5.97
-4.3%
$5.34
$3.56
$12.92
$336.91M0.41353,796 shs198,157 shs
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
$4.26
$4.23
$2.06
$4.50
$370.71M1.181.55 million shsN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
$7.19
-3.2%
$6.84
$4.58
$9.78
$360.49M1.89474,915 shs405,537 shs
Vaxart, Inc. stock logo
VXRT
Vaxart
$0.44
+8.7%
$0.46
$0.26
$1.07
$100.88M1.142.64 million shs1.69 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
0.00%-6.28%+1.36%+47.77%-47.31%
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
0.00%0.00%0.00%+5.45%+59.55%
CryoPort, Inc. stock logo
CYRX
CryoPort
0.00%-4.77%+6.05%+29.55%-15.11%
Vaxart, Inc. stock logo
VXRT
Vaxart
0.00%-1.74%-28.34%+27.94%-37.69%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
1.6176 of 5 stars
3.61.00.00.00.01.70.0
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
0.5471 of 5 stars
1.20.00.04.21.80.00.0
CryoPort, Inc. stock logo
CYRX
CryoPort
2.3903 of 5 stars
3.41.00.00.02.72.50.6
Vaxart, Inc. stock logo
VXRT
Vaxart
3.1814 of 5 stars
3.55.00.00.02.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
3.25
Buy$30.00402.51% Upside
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
2.33
Hold$4.331.72% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.75
Moderate Buy$10.8851.25% Upside
Vaxart, Inc. stock logo
VXRT
Vaxart
3.00
Buy$3.00581.82% Upside

Current Analyst Ratings Breakdown

Latest VXRT, CYRX, ATXS, and CKPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/7/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $10.00
6/13/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
5/14/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$47.00 ➝ $47.00
5/8/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/5/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00
4/29/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$47.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/AN/AN/AN/A$3.97 per shareN/A
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
$41K9,041.59N/AN/A($0.47) per share-9.06
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M1.58N/AN/A$7.44 per share0.97
Vaxart, Inc. stock logo
VXRT
Vaxart
$47.40M2.13N/AN/A$0.26 per share1.69
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$94.26M-$1.870.00N/AN/AN/A-47.18%-31.26%8/11/2025 (Estimated)
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$51.85M-$1.29N/AN/AN/AN/A-659.07%8/11/2025 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M-$2.340.00N/AN/A-50.15%-11.03%-5.54%8/5/2025 (Estimated)
Vaxart, Inc. stock logo
VXRT
Vaxart
-$66.95M-$0.27N/AN/AN/A-122.63%-91.89%-38.40%8/14/2025 (Estimated)

Latest VXRT, CYRX, ATXS, and CKPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Vaxart, Inc. stock logo
VXRT
Vaxart
-$0.08N/AN/AN/AN/AN/A
8/11/2025Q2 2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$0.61N/AN/AN/AN/AN/A
8/11/2025Q2 2025
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$0.02N/AN/AN/A$7.28 millionN/A
8/5/2025Q2 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20N/AN/AN/A$41.74 millionN/A
5/13/2025Q1 2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$0.48-$0.58-$0.10-$0.58N/AN/A
5/13/2025Q1 2025
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$0.10-$0.19-$0.09-$0.19$4.53 millionN/A
5/13/2025Q1 2025
Vaxart, Inc. stock logo
VXRT
Vaxart
-$0.07-$0.07N/A-$0.07$2.85 million$20.88 million
5/7/2025Q1 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/AN/AN/AN/AN/A
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/A
17.39
17.39
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
N/A
0.29
0.29
CryoPort, Inc. stock logo
CYRX
CryoPort
0.51
5.56
5.24
Vaxart, Inc. stock logo
VXRT
Vaxart
N/A
0.64
0.64

Institutional Ownership

CompanyInstitutional Ownership
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
98.98%
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
22.00%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Vaxart, Inc. stock logo
VXRT
Vaxart
18.05%

Insider Ownership

CompanyInsider Ownership
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
4.50%
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
2.10%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.10%
Vaxart, Inc. stock logo
VXRT
Vaxart
2.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
3056.43 million53.89 millionOptionable
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
1087.02 million47.81 millionOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.14 million45.07 millionOptionable
Vaxart, Inc. stock logo
VXRT
Vaxart
120228.91 million222.37 millionOptionable

Recent News About These Companies

OTC Markets Group Welcomes Vaxart, Inc. to OTCQX

New MarketBeat Followers Over Time

Media Sentiment Over Time

Astria Therapeutics stock logo

Astria Therapeutics NASDAQ:ATXS

$5.97 -0.27 (-4.33%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$5.96 -0.01 (-0.17%)
As of 07/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Checkpoint Therapeutics stock logo

Checkpoint Therapeutics NASDAQ:CKPT

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$7.19 -0.24 (-3.23%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$7.29 +0.10 (+1.39%)
As of 07/18/2025 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Vaxart stock logo

Vaxart NASDAQ:VXRT

$0.44 +0.04 (+8.67%)
As of 07/18/2025 03:59 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.